AIkido Pharma (NASDAQ:AIKI) Shares Cross Above 200 Day Moving Average of $2.44

AIkido Pharma Inc. (NASDAQ:AIKIGet Free Report)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.44 and traded as high as $2.47. AIkido Pharma shares last traded at $2.36, with a volume of 11,124 shares trading hands.

AIkido Pharma Trading Up 4.0 %

The stock has a 50 day moving average of $2.27 and a 200-day moving average of $2.44. The company has a market capitalization of $12.94 million, a P/E ratio of -0.61 and a beta of 0.93.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Two Sigma Advisers LP boosted its stake in AIkido Pharma by 630.0% in the 3rd quarter. Two Sigma Advisers LP now owns 86,700 shares of the business services provider’s stock worth $593,000 after purchasing an additional 74,824 shares during the period. Jane Street Group LLC boosted its stake in AIkido Pharma by 247.4% in the 1st quarter. Jane Street Group LLC now owns 100,096 shares of the business services provider’s stock worth $45,000 after purchasing an additional 71,284 shares during the period. Two Sigma Investments LP bought a new position in AIkido Pharma in the 3rd quarter worth approximately $367,000. Finally, Dimensional Fund Advisors LP boosted its stake in AIkido Pharma by 26.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 57,849 shares of the business services provider’s stock worth $396,000 after purchasing an additional 12,111 shares during the period. 10.88% of the stock is currently owned by institutional investors.

AIkido Pharma Company Profile

(Get Free Report)

AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

See Also

Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with MarketBeat.com's FREE daily email newsletter.